Description
NN1177 is a dual peptide agonist of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R).1 It induces cAMP production in BHK-21 cells expressing human GCGR or GLP-1R (EC50s = 1.83 and 0.92 pM, respectively). In vivo, NN1177 (3-5 nmol/kg) reduces body weight and cumulative food intake in a mouse model of diet-induced obesity. It also reduces body weight, hepatic fat accumulation and fibrosis, and plasma alanine transaminase (ALT) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat, high-fructose, and high-cholesterol diet.2WARNING This product is not for human or veterinary use.
References
[1] L. SIMONSEN. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls[J]. PLoS ONE, 2022. DOI:
10.1371/journal.pone.0264974[2] THOMAS MONFEUGA . Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients[J]. Molecular Metabolism, 2023, 79: Article 101850. DOI:
10.1016/j.molmet.2023.101850
